the staff said no

published

the FDA's own scientists say the evidence doesn't back compounding any of the seven peptides up for a july 23 vote, on a panel stacked with peptide-clinic insiders. plus retatrutide's full data and its asterisk, the first generic wegovy, and interpol naming peptides for the first time.

reptides dispatch · issue 03 · covering june 2026

👋 hey researchers,

issue №03. the busiest peptide-policy month we've covered, and almost everyone got the headline wrong. no, there was no " vote," and no, your peptides did not just become legal. here's what actually happened, tagged by what moved, all sourced.

the peptides go first this time.

🧪 quick check
of the seven peptides up for the FDA's july 23 compounding vote, how many did the agency's own staff say the evidence supports?
(answer at the bottom. hint: it's the number in the subject line.)
🚨regulatory

the peptide vote nobody voted on.

the internet spent the week saying the "approved" or "recommended" seven research peptides. it did neither. the Pharmacy Compounding Advisory Committee does not even meet until july 23-24, when it weighs adding bpc-157, kpv, tb-500, and mots-c on day one and dsip, semax, and epitalon on day two to the bulks list.

what actually dropped on june 29 is the opposite of the hype: the 's own staff briefing documents concluded the evidence does not support compounding any of the seven, citing missing human trials and risks of immunogenicity, toxicity, and impurity. some have never been studied in humans at all.

the twist: the panel the named the same day is stacked with peptide-business insiders instead of the usual academics. a men's-health-clinic operator and a doctor who charges $500 a consult and promotes bpc-157 on social are among them.

our read, and it cuts two ways. one, it is bullish for the research-use-only channel: with no legal compounding path, stays the only door, and that demand does not move. two, and this is the counterintuitive part, a "no" is the cleaner outcome for enforcement. a peptide that cannot be legally compounded has no grey area. selling it for human use is plainly not allowed. legalize compounding and you hand every out-of-compliance seller's lawyer a legitimacy argument to fight over. keeping it illegal keeps the line bright, and a bright line is what makes the bad actors easy to name.

none of this is settled here. written comments are due july 9, the docket closes july 22, and the panel itself votes july 23-24. we will be watching, and next issue brings what the review and the comments actually come back as.

sources:Federal Register (Docket FDA-2025-N-6895) · NPR · STAT News
🚧regulatory

the compounded-GLP-1 door is closing for good.

the side of the same fight moved forward this month. the 's proposal to leave semaglutide, tirzepatide, and liraglutide permanently off the outsourcing-facility bulks list is now in its comment window, extended to july 30. the agency cited 455-plus adverse-event reports for compounded sema and 320-plus for tirz.

sources:FDA proposed rule · june 25 extension
📈trial

retatrutide's full data landed, and so did its asterisk.

the june issue gave you the topline. at ADA on june 6 the full -1 dropped: 28.3% average weight loss at 80 weeks, 30.3% at 104 in the -35-plus arm. the biggest obesity numbers ever recorded.

the asterisk the headlines skipped: 25.3% vomiting and 11.3% dropped out at the top dose. and a 13,589-person gray-market self-report (medRxiv, june 3) found real-world users describing something more stimulant-like, appetite up, insomnia, racing heart, than the -dominated trial. the molecule and the street version are not behaving identically.

sources:Lilly TRIUMPH-1, ADA 2026 · medRxiv self-report
💊approval

the pill beat the pill.

orforglipron (), the small-molecule oral, beat oral semaglutide head-to-head at ADA: 1.9% vs 1.5% A1c, 8.2% vs 5.3% weight (ACHIEVE-3, the Lancet, june 8). meanwhile Novo's Wegovy pill crossed 3 million US scripts in five months, 80% of them in people new to GLP-1s.

sources:ACHIEVE-3, Lancet 2026 · Novo, june 7
🚨supply

interpol put peptides on the board.

for the first time, INTERPOL's Operation Pangea XVIII named peptides as a standalone enforcement target. $15.5M seized, with counterfeit GLP-1s found laced with sibutramine, a stimulant pulled from the US market in 2010 for heart attacks and strokes.

same week, Health Canada approved SEVMIA, the first generic Wegovy in a G7 market, at about $88 a month against $250-plus brand.

sources:INTERPOL · Apotex / Health Canada
🧪research

the tb-500 evidence map is mostly empty.

the first formal scoping review of tb-500 / thymosin beta-4 for musculoskeletal repair (Applied Sciences, june 19) did the thing nobody wanted to: it counted the human evidence. it is almost all preclinical, near-zero controlled human trials. the recovery peptide everyone runs has the same hole bpc-157 has.

sources:scoping review, Applied Sciences 2026
🗂️on the board

what we added this month.

five compounds joined the board this month. here is where they landed:

⚡ dispatch shots
⚔️ADA was a combo bloodbath: cagrisema 14.2%, survodutide 16.6% (but 19% quit on GI), mazdutide beat semaglutide head-to-head, 10.3% vs 6.0%.
💪a Stanford oral drug (MF-300) reversed GLP-1 muscle loss in mice without blunting fat loss. a different lever than the myostatin antibodies.
📊a 69-trial meta-analysis (Annals, june 16) kept semaglutide and tirzepatide as the weight-loss leaders; sema probably cuts mortality.
💈a GLP-1 hair-loss signal got real enough for clinician monitoring, likely shedding from fast weight loss, not the drug itself.
🧠 peptide fact
bpc-157 stands for "Body Protection Compound." it is a synthetic 15-amino-acid fragment of a protein found in human gastric juice. your own stomach lining wrote the sequence first. thirty years later, the molecule about to face an FDA panel still has zero published human RCTs behind it.
🗓 next month
next issue: august 1, 2026.
the deeper map →this was the monthly surface read. the full map lives in the brief library. paid access ($100 once, lifetime access), every reptides editorial brief.

quiz answer: zero. the 's own staff briefing documents (june 29) said the evidence supports compounding none of the seven peptides on the july 23-24 docket.

reptides editorial · research reference, not medical advice.

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.